AU Patent

AU2008221071B2 — Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof

Assigned to Bayer Intellectual Property GmbH · Expires 2014-01-16 · 12y expired

What this patent protects

The invention relates to novel 4-aryl-1,4-dihydro-1,6-naphthyridin-3- carboxamides, methods for production and use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, in parti…

USPTO Abstract

The invention relates to novel 4-aryl-1,4-dihydro-1,6-naphthyridin-3- carboxamides, methods for production and use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular, cardiovascular diseases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2008221071B2
Jurisdiction
AU
Classification
—
Expires
2014-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.